meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 1st line (L1)
1
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
versus all
vs Immunosuppressant
vs lenalidomide based treatment
vs lenalidomide and dexamethasone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab plus lenalidomide and dexamethasone
title
lenalidomide and dexamethasone
title
KEYNOTE-185, 2019 NCT02579863 multiple myeloma - 1st line (L1) 151/150
Pathology:
multiple myeloma - 1st line (L1);
multiple myeloma - 1st line (L1)
KEYNOTE-185, 2019
pembrolizumab plus lenalidomide and dexamethasone
1
T1
lenalidomide and dexamethasone
0
T0